カテゴリ： 世界, 医療/バイオ, Market Monitor Global

腫瘍壊死因子受容体スーパーファミリーメンバー4のグローバル市場展望 2023年-2029年：ATOR-1015、ENUM-004、GBR-8383、GSK-3174998、その他

■ 英語タイトル：Tumor Necrosis Factor Receptor Superfamily Member 4 Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23LY8728）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23LY8728
■ 発行日：2023年7月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：79
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥487,500見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥633,750見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥731,250見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[腫瘍壊死因子受容体スーパーファミリーメンバー4のグローバル市場展望 2023年-2029年：ATOR-1015、ENUM-004、GBR-8383、GSK-3174998、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の腫瘍壊死因子受容体スーパーファミリーメンバー4市場規模と予測を収録しています。・世界の腫瘍壊死因子受容体スーパーファミリーメンバー4市場：売上、2018年-2023年、2024年-2029年
・世界の腫瘍壊死因子受容体スーパーファミリーメンバー4市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の腫瘍壊死因子受容体スーパーファミリーメンバー4市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ATOR-1015」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

腫瘍壊死因子受容体スーパーファミリーメンバー4のグローバル主要企業は、Abeome Corp、 Alligator Bioscience AB、 Apogenix GmbH、 BioInvent International AB、 Bristol-Myers Squibb Company、 Denceptor Therapeutics Ltd、 Enumeral Biomedical Holdings Inc、 GlaxoSmithKline Plc、 Glenmark Pharmaceuticals Ltd、 Incyte Corp、 Kyowa Hakko Kirin Co Ltd、 MedImmune LLC、 Pfizer Incなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、腫瘍壊死因子受容体スーパーファミリーメンバー4のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の腫瘍壊死因子受容体スーパーファミリーメンバー4市場：タイプ別、2018年-2023年、2024年-2029年
世界の腫瘍壊死因子受容体スーパーファミリーメンバー4市場：タイプ別市場シェア、2022年
・ATOR-1015、ENUM-004、GBR-8383、GSK-3174998、その他

世界の腫瘍壊死因子受容体スーパーファミリーメンバー4市場：用途別、2018年-2023年、2024年-2029年
世界の腫瘍壊死因子受容体スーパーファミリーメンバー4市場：用途別市場シェア、2022年
・口腔科、免疫科、皮膚科、消化器科、その他

世界の腫瘍壊死因子受容体スーパーファミリーメンバー4市場：地域・国別、2018年-2023年、2024年-2029年
世界の腫瘍壊死因子受容体スーパーファミリーメンバー4市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における腫瘍壊死因子受容体スーパーファミリーメンバー4のグローバル売上、2018年-2023年
・主要企業における腫瘍壊死因子受容体スーパーファミリーメンバー4のグローバル売上シェア、2022年
・主要企業における腫瘍壊死因子受容体スーパーファミリーメンバー4のグローバル販売量、2018年-2023年
・主要企業における腫瘍壊死因子受容体スーパーファミリーメンバー4のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Abeome Corp、 Alligator Bioscience AB、 Apogenix GmbH、 BioInvent International AB、 Bristol-Myers Squibb Company、 Denceptor Therapeutics Ltd、 Enumeral Biomedical Holdings Inc、 GlaxoSmithKline Plc、 Glenmark Pharmaceuticals Ltd、 Incyte Corp、 Kyowa Hakko Kirin Co Ltd、 MedImmune LLC、 Pfizer Inc

*************************************************************

・調査・分析レポートの概要
腫瘍壊死因子受容体スーパーファミリーメンバー4市場の定義
市場セグメント
世界の腫瘍壊死因子受容体スーパーファミリーメンバー4市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の腫瘍壊死因子受容体スーパーファミリーメンバー4市場規模
世界の腫瘍壊死因子受容体スーパーファミリーメンバー4市場規模：2022年 VS 2029年
世界の腫瘍壊死因子受容体スーパーファミリーメンバー4市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの腫瘍壊死因子受容体スーパーファミリーメンバー4の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の腫瘍壊死因子受容体スーパーファミリーメンバー4製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：ATOR-1015、ENUM-004、GBR-8383、GSK-3174998、その他
腫瘍壊死因子受容体スーパーファミリーメンバー4のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：口腔科、免疫科、皮膚科、消化器科、その他
腫瘍壊死因子受容体スーパーファミリーメンバー4の用途別グローバル売上・予測

・地域別市場分析
地域別腫瘍壊死因子受容体スーパーファミリーメンバー4市場規模 2022年と2029年
地域別腫瘍壊死因子受容体スーパーファミリーメンバー4売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Abeome Corp、 Alligator Bioscience AB、 Apogenix GmbH、 BioInvent International AB、 Bristol-Myers Squibb Company、 Denceptor Therapeutics Ltd、 Enumeral Biomedical Holdings Inc、 GlaxoSmithKline Plc、 Glenmark Pharmaceuticals Ltd、 Incyte Corp、 Kyowa Hakko Kirin Co Ltd、 MedImmune LLC、 Pfizer Inc
...

This report aims to provide a comprehensive presentation of the global market for Tumor Necrosis Factor Receptor Superfamily Member 4, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Necrosis Factor Receptor Superfamily Member 4. This report contains market size and forecasts of Tumor Necrosis Factor Receptor Superfamily Member 4 in global, including the following market information:
Global Tumor Necrosis Factor Receptor Superfamily Member 4 Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Tumor Necrosis Factor Receptor Superfamily Member 4 Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Tumor Necrosis Factor Receptor Superfamily Member 4 companies in 2022 (%)
The global Tumor Necrosis Factor Receptor Superfamily Member 4 market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
ATOR-1015 Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 4 include Abeome Corp, Alligator Bioscience AB, Apogenix GmbH, BioInvent International AB, Bristol-Myers Squibb Company, Denceptor Therapeutics Ltd, Enumeral Biomedical Holdings Inc, GlaxoSmithKline Plc and Glenmark Pharmaceuticals Ltd, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Tumor Necrosis Factor Receptor Superfamily Member 4 manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Tumor Necrosis Factor Receptor Superfamily Member 4 Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Tumor Necrosis Factor Receptor Superfamily Member 4 Market Segment Percentages, by Type, 2022 (%)
ATOR-1015
ENUM-004
GBR-8383
GSK-3174998
Others
Global Tumor Necrosis Factor Receptor Superfamily Member 4 Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Tumor Necrosis Factor Receptor Superfamily Member 4 Market Segment Percentages, by Application, 2022 (%)
Oocology
Immunology
Dermatology
Gastrointestinal
Others
Global Tumor Necrosis Factor Receptor Superfamily Member 4 Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Tumor Necrosis Factor Receptor Superfamily Member 4 Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Tumor Necrosis Factor Receptor Superfamily Member 4 revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Tumor Necrosis Factor Receptor Superfamily Member 4 revenues share in global market, 2022 (%)
Key companies Tumor Necrosis Factor Receptor Superfamily Member 4 sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Tumor Necrosis Factor Receptor Superfamily Member 4 sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Abeome Corp
Alligator Bioscience AB
Apogenix GmbH
BioInvent International AB
Bristol-Myers Squibb Company
Denceptor Therapeutics Ltd
Enumeral Biomedical Holdings Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Incyte Corp
Kyowa Hakko Kirin Co Ltd
MedImmune LLC
Pfizer Inc
Outline of Major Chapters:
Chapter 1: Introduces the definition of Tumor Necrosis Factor Receptor Superfamily Member 4, market overview.
Chapter 2: Global Tumor Necrosis Factor Receptor Superfamily Member 4 market size in revenue and volume.
Chapter 3: Detailed analysis of Tumor Necrosis Factor Receptor Superfamily Member 4 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Tumor Necrosis Factor Receptor Superfamily Member 4 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Tumor Necrosis Factor Receptor Superfamily Member 4 capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Tumor Necrosis Factor Receptor Superfamily Member 4 Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Tumor Necrosis Factor Receptor Superfamily Member 4 Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Tumor Necrosis Factor Receptor Superfamily Member 4 Overall Market Size
2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size: 2022 VS 2029
2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 4 Sales: 2018-2029
3 Company Landscape
3.1 Top Tumor Necrosis Factor Receptor Superfamily Member 4 Players in Global Market
3.2 Top Global Tumor Necrosis Factor Receptor Superfamily Member 4 Companies Ranked by Revenue
3.3 Global Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue by Companies
3.4 Global Tumor Necrosis Factor Receptor Superfamily Member 4 Sales by Companies
3.5 Global Tumor Necrosis Factor Receptor Superfamily Member 4 Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Tumor Necrosis Factor Receptor Superfamily Member 4 Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Tumor Necrosis Factor Receptor Superfamily Member 4 Product Type
3.8 Tier 1, Tier 2 and Tier 3 Tumor Necrosis Factor Receptor Superfamily Member 4 Players in Global Market
3.8.1 List of Global Tier 1 Tumor Necrosis Factor Receptor Superfamily Member 4 Companies
3.8.2 List of Global Tier 2 and Tier 3 Tumor Necrosis Factor Receptor Superfamily Member 4 Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size Markets, 2022 & 2029
4.1.2 ATOR-1015
4.1.3 ENUM-004
4.1.4 GBR-8383
4.1.5 GSK-3174998
4.1.6 Others
4.2 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue & Forecasts
4.2.1 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue, 2018-2023
4.2.2 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue, 2024-2029
4.2.3 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue Market Share, 2018-2029
4.3 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Sales & Forecasts
4.3.1 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Sales, 2018-2023
4.3.2 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Sales, 2024-2029
4.3.3 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Sales Market Share, 2018-2029
4.4 By Type – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2022 & 2029
5.1.2 Oocology
5.1.3 Immunology
5.1.4 Dermatology
5.1.5 Gastrointestinal
5.1.6 Others
5.2 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue & Forecasts
5.2.1 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue, 2018-2023
5.2.2 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue, 2024-2029
5.2.3 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue Market Share, 2018-2029
5.3 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Sales & Forecasts
5.3.1 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Sales, 2018-2023
5.3.2 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Sales, 2024-2029
5.3.3 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Sales Market Share, 2018-2029
5.4 By Application – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2022 & 2029
6.2 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue & Forecasts
6.2.1 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue, 2018-2023
6.2.2 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue, 2024-2029
6.2.3 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue Market Share, 2018-2029
6.3 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Sales & Forecasts
6.3.1 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Sales, 2018-2023
6.3.2 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Sales, 2024-2029
6.3.3 By Region – Global Tumor Necrosis Factor Receptor Superfamily Member 4 Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue, 2018-2029
6.4.2 By Country – North America Tumor Necrosis Factor Receptor Superfamily Member 4 Sales, 2018-2029
6.4.3 US Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.4.4 Canada Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.4.5 Mexico Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue, 2018-2029
6.5.2 By Country – Europe Tumor Necrosis Factor Receptor Superfamily Member 4 Sales, 2018-2029
6.5.3 Germany Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.5.4 France Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.5.5 U.K. Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.5.6 Italy Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.5.7 Russia Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.5.8 Nordic Countries Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.5.9 Benelux Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue, 2018-2029
6.6.2 By Region – Asia Tumor Necrosis Factor Receptor Superfamily Member 4 Sales, 2018-2029
6.6.3 China Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.6.4 Japan Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.6.5 South Korea Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.6.6 Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.6.7 India Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue, 2018-2029
6.7.2 By Country – South America Tumor Necrosis Factor Receptor Superfamily Member 4 Sales, 2018-2029
6.7.3 Brazil Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.7.4 Argentina Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 4 Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 4 Sales, 2018-2029
6.8.3 Turkey Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.8.4 Israel Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.8.5 Saudi Arabia Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
6.8.6 UAE Tumor Necrosis Factor Receptor Superfamily Member 4 Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Abeome Corp
7.1.1 Abeome Corp Company Summary
7.1.2 Abeome Corp Business Overview
7.1.3 Abeome Corp Tumor Necrosis Factor Receptor Superfamily Member 4 Major Product Offerings
7.1.4 Abeome Corp Tumor Necrosis Factor Receptor Superfamily Member 4 Sales and Revenue in Global (2018-2023)
7.1.5 Abeome Corp Key News & Latest Developments
7.2 Alligator Bioscience AB
7.2.1 Alligator Bioscience AB Company Summary
7.2.2 Alligator Bioscience AB Business Overview
7.2.3 Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 4 Major Product Offerings
7.2.4 Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 4 Sales and Revenue in Global (2018-2023)
7.2.5 Alligator Bioscience AB Key News & Latest Developments
7.3 Apogenix GmbH
7.3.1 Apogenix GmbH Company Summary
7.3.2 Apogenix GmbH Business Overview
7.3.3 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 4 Major Product Offerings
7.3.4 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 4 Sales and Revenue in Global (2018-2023)
7.3.5 Apogenix GmbH Key News & Latest Developments
7.4 BioInvent International AB
7.4.1 BioInvent International AB Company Summary
7.4.2 BioInvent International AB Business Overview
7.4.3 BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 4 Major Product Offerings
7.4.4 BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 4 Sales and Revenue in Global (2018-2023)
7.4.5 BioInvent International AB Key News & Latest Developments
7.5 Bristol-Myers Squibb Company
7.5.1 Bristol-Myers Squibb Company Company Summary
7.5.2 Bristol-Myers Squibb Company Business Overview
7.5.3 Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 4 Major Product Offerings
7.5.4 Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 4 Sales and Revenue in Global (2018-2023)
7.5.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.6 Denceptor Therapeutics Ltd
7.6.1 Denceptor Therapeutics Ltd Company Summary
7.6.2 Denceptor Therapeutics Ltd Business Overview
7.6.3 Denceptor Therapeutics Ltd Tumor Necrosis Factor Receptor Superfamily Member 4 Major Product Offerings
7.6.4 Denceptor Therapeutics Ltd Tumor Necrosis Factor Receptor Superfamily Member 4 Sales and Revenue in Global (2018-2023)
7.6.5 Denceptor Therapeutics Ltd Key News & Latest Developments
7.7 Enumeral Biomedical Holdings Inc
7.7.1 Enumeral Biomedical Holdings Inc Company Summary
7.7.2 Enumeral Biomedical Holdings Inc Business Overview
7.7.3 Enumeral Biomedical Holdings Inc Tumor Necrosis Factor Receptor Superfamily Member 4 Major Product Offerings
7.7.4 Enumeral Biomedical Holdings Inc Tumor Necrosis Factor Receptor Superfamily Member 4 Sales and Revenue in Global (2018-2023)
7.7.5 Enumeral Biomedical Holdings Inc Key News & Latest Developments
7.8 GlaxoSmithKline Plc
7.8.1 GlaxoSmithKline Plc Company Summary
7.8.2 GlaxoSmithKline Plc Business Overview
7.8.3 GlaxoSmithKline Plc Tumor Necrosis Factor Receptor Superfamily Member 4 Major Product Offerings
7.8.4 GlaxoSmithKline Plc Tumor Necrosis Factor Receptor Superfamily Member 4 Sales and Revenue in Global (2018-2023)
7.8.5 GlaxoSmithKline Plc Key News & Latest Developments
7.9 Glenmark Pharmaceuticals Ltd
7.9.1 Glenmark Pharmaceuticals Ltd Company Summary
7.9.2 Glenmark Pharmaceuticals Ltd Business Overview
7.9.3 Glenmark Pharmaceuticals Ltd Tumor Necrosis Factor Receptor Superfamily Member 4 Major Product Offerings
7.9.4 Glenmark Pharmaceuticals Ltd Tumor Necrosis Factor Receptor Superfamily Member 4 Sales and Revenue in Global (2018-2023)
7.9.5 Glenmark Pharmaceuticals Ltd Key News & Latest Developments
7.10 Incyte Corp
7.10.1 Incyte Corp Company Summary
7.10.2 Incyte Corp Business Overview
7.10.3 Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 4 Major Product Offerings
7.10.4 Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 4 Sales and Revenue in Global (2018-2023)
7.10.5 Incyte Corp Key News & Latest Developments
7.11 Kyowa Hakko Kirin Co Ltd
7.11.1 Kyowa Hakko Kirin Co Ltd Company Summary
7.11.2 Kyowa Hakko Kirin Co Ltd Tumor Necrosis Factor Receptor Superfamily Member 4 Business Overview
7.11.3 Kyowa Hakko Kirin Co Ltd Tumor Necrosis Factor Receptor Superfamily Member 4 Major Product Offerings
7.11.4 Kyowa Hakko Kirin Co Ltd Tumor Necrosis Factor Receptor Superfamily Member 4 Sales and Revenue in Global (2018-2023)
7.11.5 Kyowa Hakko Kirin Co Ltd Key News & Latest Developments
7.12 MedImmune LLC
7.12.1 MedImmune LLC Company Summary
7.12.2 MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 4 Business Overview
7.12.3 MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 4 Major Product Offerings
7.12.4 MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 4 Sales and Revenue in Global (2018-2023)
7.12.5 MedImmune LLC Key News & Latest Developments
7.13 Pfizer Inc
7.13.1 Pfizer Inc Company Summary
7.13.2 Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 4 Business Overview
7.13.3 Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 4 Major Product Offerings
7.13.4 Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 4 Sales and Revenue in Global (2018-2023)
7.13.5 Pfizer Inc Key News & Latest Developments
8 Global Tumor Necrosis Factor Receptor Superfamily Member 4 Production Capacity, Analysis
8.1 Global Tumor Necrosis Factor Receptor Superfamily Member 4 Production Capacity, 2018-2029
8.2 Tumor Necrosis Factor Receptor Superfamily Member 4 Production Capacity of Key Manufacturers in Global Market
8.3 Global Tumor Necrosis Factor Receptor Superfamily Member 4 Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Tumor Necrosis Factor Receptor Superfamily Member 4 Supply Chain Analysis
10.1 Tumor Necrosis Factor Receptor Superfamily Member 4 Industry Value Chain
10.2 Tumor Necrosis Factor Receptor Superfamily Member 4 Upstream Market
10.3 Tumor Necrosis Factor Receptor Superfamily Member 4 Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Tumor Necrosis Factor Receptor Superfamily Member 4 Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 腫瘍壊死因子受容体スーパーファミリーメンバー1Aのグローバル市場展望 2023年-2029年：LY-3232094、EYS-606、SRT-100、その他
  • 腫瘍壊死因子受容体スーパーファミリーメンバー18のグローバル市場展望 2023年-2029年：AMG-228、BMS-986156、FPA-154、GWN-323、INCAGN-1876、その他
  • バソプレシンV1b受容体のグローバル市場展望 2023年-2029年：PHT-103、ABT-436、AVN-628、その他
  • 肺腫瘍塞栓術のグローバル市場展望 2023年-2029年：肝動脈化学塞栓術（TACE）、肝動脈放射線塞栓術（TARE）、その他
  • C5aアナフィラトキシン走化性受容体1のグローバル市場展望 2023年-2029年：EP-67、NOXD-19、NOXD-20、DF-2593A、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23LY8728 )"腫瘍壊死因子受容体スーパーファミリーメンバー4のグローバル市場展望 2023年-2029年：ATOR-1015、ENUM-004、GBR-8383、GSK-3174998、その他" (英文：Tumor Necrosis Factor Receptor Superfamily Member 4 Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。